The SparX Selected IO & Nab2-ADC Pipeline
| Candidate | Target | Research | Lead Optimization | Pre-Clinical Development | IND-Enabling | Phase I | Phase II |
|---|---|---|---|---|---|---|---|
| SPX-303 | LILRB2xPDL1 |
 Mayo Clinic (Minnesota, Arizona & Florida)  HonorHealth
|
First-in-Class | ||||
| LILRB2xPDL1+T-DXd |
MRCT & in combination with T-DXd
| First-in-Class | |||||
| SPX-629 | HER2 Dual-Payload ADC (TOP1i × MMAE) |
| Best-in-Class | ||||
| SPX-602 | VEGFxPDL1-ADC (TOP1i × MMAE) |
| First-in-Class | ||||
| SPX-608 | Immune-Targeting Dual Payload ADC |
| Open for Collaboration | First-in-Class | |||
| TAA-ADC | Nab²™ Dual-Payload ADC Platform |
| Platform Collaboration | First-in-Class | |||
| SPX-306 | Oral IL23xTL1A |
| NewCo Collaboration | First-in-Class | |||
| ALA-105 | CLDN 18.2-iNKT |
| Arovella Collaboration | First-in-Class | |||
| SPX-701 | Bispecific Antibody |
| MNC Collaboration | First-in-Class | |||
| SPX-308 | VEGF x PD-L1 biparatopic |
| Open for Collaboration | Best-in-Class | |||
SPX-303* Target: αLILRB2 X PD-L1
Research | Lead Optimization | Pre-Clinical Development | IND-Enabling | Phase 1
SPX-104 Target: αLILRB2 + PD-1
Research | Lead Optimization | Pre-Clinical Development | IND-Enabling
SPX-308* Target: sdVEGF X sdPD-L1
Research | Lead Optimization | Pre-Clinical Development
SPX-1011 Target: CLDN 18.2
Research | Lead Optimization | Pre-Clinical Development | IND-Enabling | Phase 1
SPX-102* Target: CLDN 18.2-CDx
Research | Lead Optimization | Pre-Clinical Development | IND-Enabling | Phase 1
SPX-306+,1 Target: Undisclosed
Research | Lead Optimization | Pre-Clinical Development | IND-Enabling
SPX-603* Target: VEGFxPD-L1-ADC
Research | Lead Optimization | Pre-Clinical Development
Candidate: SPX-101 | Target: CLDN 18.2
Discovery | Pharmacology | GLD/GLP | IND Enabling | IND | Phase 1
Candidate: SPX-102 | Target: CLDN 18.2
Discovery | Pharmacology | GLD/GLP | IND Enabling | IND | Phase 1
Candidate: SPX-104 | Target: LILRB2
Discovery | Pharmacology | GLD/GLP
Candidate: SPX-301 | Target: CLDN X Chkpt
Discovery | Pharmacology
Candidate: SPX-302 | Target: Bispecific
Discovery | Pharmacology | GLD/GLP | IND Enabling
Candidate: SPX-303 | Target: LILRB2 X Chkpt
Discovery | Pharmacology | GLD/GLP
Candidate: SPX-304 | Target: Bispecific
Discovery | Pharmacology
Candidate: SPX-306 | Target: Bispecific
Discovery | Pharmacology
- Internal Pipeline
- Collaboration Pipeline
